Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1999;34:1041-1046

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Modena, M. G.
Right arrow Articles by Rossi, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Modena, M. G.
Right arrow Articles by Rossi, R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ESTRADIOL
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Other hypertension
Right arrow Hypertrophy
Right arrow Echocardiography

(Hypertension. 1999;34:1041-1046.)
© 1999 American Heart Association, Inc.


Scientific Contributions

Effects of Transdermal 17ß-Estradiol on Left Ventricular Anatomy and Performance in Hypertensive Women

Maria Grazia Modena; Nicola Muia, Jr; Pietro Aveta; Rosella Molinari; Rosario Rossi

From the Institute of Cardiology II, Department of Internal Medicine, University of Modena, Italy.

Correspondence to Maria Grazia Modena, MD, FESC, FACC, Institute of Cardiology II, Policlinico Hospital, Via del Pozzo, 71, 41100 Modena, Italy. E-mail modena.m{at}policlinico.mo.it

Abstract—To reduce cardiovascular complications, antihypertensive therapy should not only normalize blood pressure but also induce a regression of structural abnormalities, which are the expression of end-organ damage. We investigated the effects of transdermal 17ß-estradiol, combined with standard antihypertensive therapy, on the modification of left ventricular anatomy and systolic performance in hypertensive postmenopausal women. In a randomized, double-blind, placebo-controlled study, we enrolled 169 postmenopausal women with mild or moderate hypertension. Eighty-six patients (group 1) received transdermal 17ß-estradiol (50 µg/d) and norethisterone acetate (2.5 mg/d, orally), and 83 patients (group 2) received placebo. At baseline, all women underwent M-mode and 2-D echocardiogram, which was repeated after 6, 12, and 18 months of follow-up. After 18 months of treatment, we observed a significant decrease in left ventricular diastolic septal and posterior wall thickness and mass in both groups. Furthermore, after 18 months, left ventricular mass was significantly less than in the estrogen-treated group. No significant modifications were observed in left ventricular systolic and diastolic dimensions or in systolic performance, as expressed by left ventricular fractional shortening. In conclusion, transdermal 17ß-estradiol, which is associated with antihypertensive therapy, may contribute in the reduction of left ventricular mass in hypertensive postmenopausal women.


Key Words: hypertension, mild • hypertrophy • trials • drugs • estrogen • menopause • echocardiography




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
V. Jazbutyte, P. A. Arias-Loza, K. Hu, J. Widder, V. Govindaraj, C. von Poser-Klein, J. Bauersachs, K.-H. Fritzemeier, C. Hegele-Hartung, L. Neyses, et al.
Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats
Cardiovasc Res, March 1, 2008; 77(4): 774 - 781.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. F. Deschepper and B. Llamas
Hypertensive Cardiac Remodeling in Males and Females: From the Bench to the Bedside
Hypertension, March 1, 2007; 49(3): 401 - 407.
[Full Text] [PDF]


Home page
CirculationHome page
T. Pelzer, P.-A. A. Loza, K. Hu, B. Bayer, C. Dienesch, L. Calvillo, J. F. Couse, K. S. Korach, L. Neyses, and G. Ertl
Increased Mortality and Aggravation of Heart Failure in Estrogen Receptor-{beta} Knockout Mice After Myocardial Infarction
Circulation, March 29, 2005; 111(12): 1492 - 1498.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
L. H Naylor, L. F Arnolda, J. A Deague, D. Playford, A. Maurogiovanni, G. O'Driscoll, and D. J Green
Reduced ventricular flow propagation velocity in elite athletes is augmented with the resumption of exercise training
J. Physiol., March 15, 2005; 563(3): 957 - 963.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. van Eickels, R. D. Patten, M. J. Aronovitz, A. Alsheikh-Ali, K. Gostyla, F. Celestin, C. Grohe, M. E. Mendelsohn, and R. H. Karas
17-Beta-Estradiol increases cardiac remodeling and mortality in mice with myocardial infarction
J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2084 - 2092.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Xu, I. A Arenas, S. J Armstrong, and S. T Davidge
Estrogen modulation of left ventricular remodeling in the aged heart
Cardiovasc Res, February 1, 2003; 57(2): 388 - 394.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. G. ROSTAND
Coronary Heart Disease in Chronic Renal Insufficiency: Some Management Considerations
J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1948 - 1956.
[Full Text]